Skip to main content
    B

    Barinthus Biotherapeutics plc (BRNS)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • PINK

    $0.74
    +0.00 (+0.00%)

    Market Cap: $30.23M

    Last updated: Nov 16, 2026 at 4:00 PM ET

    Barinthus Biotherapeutics plc (BRNS) Statistics

    Updated Nov 16, 2026. Figures from company filings and market prices; estimates from consensus analysts.

    Barinthus Biotherapeutics (BRNS) has a market cap of $30.23M. Revenue fell 100.00% over the last 12 months from the 12 months before.

    Total Valuation

    Market Cap$30.23M
    Close (Nov 16, 2026)$0.74

    Key Dates

    The next earnings report is expected on Mar 11, 2027, covering the quarter ending Dec 31, 2026.

    Next Earnings DateMar 11, 2027 (expected)
    Last Earnings DateAug 6, 2026
    Fiscal Year EndDecember

    Share Statistics

    The share count held steady in the quarter ended Jun 30, 2026 and grew 2.29% a year over 2 years.

    Shares Outstanding40.85M
    Shares Change (YoY)+1.25%
    Shares Change (QoQ)0.00%
    Share Count Growth (2Y CAGR)+2.29%

    Valuation Ratios

    P/B Ratio0.5x
    P/TBV Ratio0.7x

    Price Statistics

    The stock is down 5.36% over 52 weeks and trades at its 50-day average.

    Beta (1Y)0.73
    52-Week Change-5.36%
    3-Month Change+19.37%
    6-Month Change+15.91%
    5-Year Change-94.64%
    Total Return (1Y)-5.36%
    Total Return (3Y CAGR)-35.46%
    Total Return (5Y CAGR)-43.46%
    Max Drawdown (1Y)-32.06%
    Max Drawdown (3Y)-85.40%
    Sharpe Ratio (1Y)0.06
    Correlation with SPY (1Y)0.16
    50-Day Average$0.74
    200-Day Average$0.66
    52-Week Range$0.51 to $0.85
    RSI (14 Days)60.3

    The 5-year change compares month-end closes, adjusted for splits, through Oct 2026.

    Price chart

    Financial Position

    Current assets cover 5.54x current liabilities.

    Current Ratio5.54x
    Quick Ratio5.54x
    Interest Coverage-796.09x

    Returns and Efficiency

    Return on equity is -73.14% over the last 12 months, against a 5-year average of -38.79%.

    Return on Equity (ROE)-73.14%
    Return on Assets (ROA)-50.97%
    Return on Capital Employed (ROCE)-59.83%
    ROE (5Y Average)-38.79%
    ROA (5Y Average)-31.25%
    ROIC (5Y Average)-38.28%

    Scores

    BRNS has a Piotroski F-Score of 1 of 9, in the weak band of 0 to 2.

    Piotroski F-Score1 of 9
    Piotroski StrengthWeak

    Income Statement

    Revenue was $0 over the last 12 months.

    Revenue$0
    Revenue Growth (YoY)-100.00%
    Operating Income-$44.60M
    Pretax Income-$42.21M
    Net Income-$41.74M
    EBITDA-$38.67M
    EBIT-$42.16M
    Reported EPS (TTM)-$0.91

    Trailing 12 months through Jun 30, 2026.

    Full financial statements

    Balance Sheet

    Shareholder equity funds 69.69% of the $81.89M in total assets.

    Cash and Equivalents$59.30M
    Working Capital$51.85M
    Shareholder Equity$57.07M
    Tangible Book Value$44.03M
    Total Assets$81.89M
    Total Liabilities$24.76M

    Balance sheet as of Jun 30, 2026.

    Full balance sheet

    Cash Flow

    After $234 of capital spending, operating cash flow left -$26.43M of free cash flow.

    Operating Cash Flow-$26.43M
    Capital Expenditures$234
    Free Cash Flow-$26.43M
    FCF Per Share-$0.65
    Depreciation and Amortization$3.49M

    Trailing 12 months through Jun 30, 2026.

    Full cash flow statement

    Price Target

    Analyst price targets are part of paid GNG plans. See plans

    Frequently Asked Questions About BRNS

    What is BRNS's market cap?

    Barinthus Biotherapeutics has a market cap of $30.23M.

    How many shares of BRNS are outstanding?

    Barinthus Biotherapeutics has 40.85M shares outstanding. The count is up 1.25% from a year earlier.

    Does BRNS pay a dividend?

    No. Barinthus Biotherapeutics does not pay a dividend.